Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Labor Day. We will reopen on Tuesday, September 2nd.

Thank you for your patience.

To Purchase # 8905SC

8905SC 5 µg (With Carrier) $199.00
8905SF 5 µg (Carrier Free) $199.00
8905LC 25 µg (With Carrier) $599.00
8905LF 25 µg (Carrier Free) $599.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-13 (hIL-13) Gly21-Asn132 (Accession #AAK53823) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-13. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIL-13 does not have a Met on the amino terminus and has a calculated MW of 13,921. DTT-reduced and non-reduced protein migrate as 12 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal GPVPP of recombinant hIL-13 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-13 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.6-1.2 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg hIL-13.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (6). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,6,7). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,4,5) and modulates resistance to parasitic organisms (1).


1.  Wynn, T.A. (2003) Annu Rev Immunol 21, 425-56.

2.  Katz, Y. et al. (1995) Clin Exp Immunol 101, 150-6.

3.  Nakajima, H. and Takatsu, K. (2007) Int Arch Allergy Immunol 142, 265-73.

4.  McKenzie, A.N. et al. (1993) Proc Natl Acad Sci USA 90, 3735-9.

5.  Wills-Karp, M. and Finkelman, F.D. (2008) Sci Signal 1, pe55.

6.  Wills-Karp, M. et al. (1998) Science 282, 2258-61.

7.  Mentink-Kane, M.M. et al. (2004) Proc Natl Acad Sci USA 101, 586-90.


Entrez-Gene Id 3596
Swiss-Prot Acc. P35225


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.